Amyloidosis News - March 2021

The ANDROMEDA study revealed a significant hematologic complete response rate in patients with newly diagnosed light chain amyloidosis treated with daratumumab plus hyaluronidase human-fihj. Read More ›

Other amyloid subtypes may also cause myocardial pyrophosphate radiotracer uptake, highlighting the need for caution when using noninvasive diagnostic approaches. Read More ›

Clinicians need to be aware of potential signals of hereditary transthyretin amyloidosis that most commonly present in the year before diagnosis. Read More ›

Clinical signals and features of positive PYP transthyretin cardiac amyloidosis highlight the need for early diagnosis. Read More ›

The presence of severe aortic stenosis in the context of transthyretin cardiac amyloidosis is associated with a dramatic reduction in patient survival. Read More ›

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.